Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 11, 2013
For more info, visit http://www.bio-rad.com/yt/11/Bio-Plex. In this webinar, Dr. Dominic Eisinger describes the development and validation of a multiplex biomarker panel for quantifying the commitment, onset, and induction of apoptosis by the intrinsic pathway in tumor tissue samples.
Fourteen bead-based immunoassays for apoptosis-associated proteins were developed on the Myriad RBM multi-analyte profile (MAP) platform, which is based on Luminex xMAP technology. All assays were confirmed by IP-western blotting with the same antibody pairs used in the bead-based sandwich assays.
The assays were manufactured as three panels: Panel 1: BAK, BAX, lamin B (intact +45 kDa), and SMAC Panel 2: BAD, BAX/BCL-2 heterodimer, BCL-xl, BIM, and Mcl-1 Panel 3: Active caspase-3, BCL-xl/BAK heterodimer, MCL-1/BAK heterodimer, pBAD, and survivin
Each assay was validated for precision, linearity, and accuracy for use with tumor biopsies, cell lysates, and tissue lysates. The quantitative assays were found to be more sensitive than IP-westerns.
Presenter: Dominic Eisinger, PhD Director of Strategic Development, Myriad RBM
Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges.